NDA 203159/S-012

SUPPLEMENT APPROVAL

Bayer HealthCare Pharmaceutical Inc.
Attention: Alicia Lowery
Assistant Director,Regulatory Affairs Strategy
100 Bayer Blvd., P.O. Box 915
Whippany, NJ 07981-0915

Dear Ms. Lowery:

Please refer to your supplemental new drug application (sNDA) dated and received September 9, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Skyla (levonorgestrel-releasing intrauterine system)(LNG IUS).

This Prior Approval supplemental new drug application provides for revisions to the following:

Physician Insert (PI):

Highlights:

- Added Recent Major Changes to indicate a revised Warnings and Precautions subsection.

Dosage and Administration Section:

- Moved the recommendation for preinsertion evaluation
- Removed all references to Patient Information Booklet and Consent Form

Warning and Precautions:

- Updated Risk with Intrauterine Pregnancy subsection language with the risk of virilization

Use in Specific Populations:

- Updated Pregnancy subsection language with the risk of virilization

Patient Counseling Information:

- Updated Risk of Intrauterine Pregnancy language with the risk of virilization
- Removed reference to Reminder Card

Patient Package Insert (PPI):

- Updated the language "*What if I become pregnant while using Skyla?*", "*Can I use tampons with Skyla?*" and "*What are the possible side effects of Skyla?*" subsections
- Added language on the use of menstrual cups
- Added common Adverse Events

Additional edits to the PI and PPI were made to harmonize with other approved LNG IUS products.

Carton and Patient Information Booklet:

- Deleted all references to the Consent Form and Reminder Card

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton labeling submitted on September 9, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Final Printed Carton and Container Labeling for approved NDA 203159/S-012**." Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Charlene Williamson, Regulatory Project Manager, at (301) 796-1025.

Sincerely,

{See appended electronic signature page}

Audrey Gassman, M.D.
Deputy Director
Division of Urology, Obstetrics, and Gynecology
Office of Rare Diseases, Pediatrics, Urologic, and Reproductive Products
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
- Carton Labeling
- Patient Information Booklet

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

AUDREY L GASSMAN
05/17/2021 03:07:35 PM